| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Grants Atrovent Nasal Spray Pediatric Indication For Rhinorrhea RIDGEFIELD, CT -- Sept. 1, 1998 -- Boehringer Ingelheim Pharmaceuticals, Inc.’ s Atrovent(R) (ipratropium bromide) Nasal Spray .03% for the treatment of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis has now been granted and indication for use in children six years and up by the United States Food and Drug Administration. It is not indicated for the relief of nasal congestion, sneezing or postnasal drip. Atrovent Nasal Spray .03% is an anticholinergic agent that blocks the action of acetylcholine, which causes a runny nose. It provides significant relief from the first day of therapy, with no nasal rebound. In clinical trials, the most frequently reported nasal adverse events were transient episodes of epistaxis (9.0 percent versus 4.6 percent with vehicle) or nasal dryness (5.1 percent versus 0.9 percent with vehicle). The most frequently reported non-nasal adverse events were transient episodes of headache (9.8 percent versus 9.2 percent with vehicle) or upper respiratory tract infections (9.8 percent versus 7.2 percent with vehicle). Related Links: Atrovent, Boehringer Ingelheim Pharmaceuticals, Inc
|